Skip to main content
. 2014 Dec;32(4):226–231. doi: 10.3109/02813432.2014.984952

Table I.

Characteristics of all 2274 patients with atrial fibrillation, n (%).

OAC treatment (n = 1087) No OAC treatment (n = 1187)
Age, years:
 Age 0–64 years 140 (12.9) 260 (21.9)
 Age 65–74 years 320 (29.4) 251 (21.1)
 Age 75–89 years 607 (55.8) 547 (46.1)
 Age 90 years and more 20 (1.8) 129 (10.9)
Female sex 473 (43.5) 496 (41.8)
Type of AF:
 Isolated episode of AF 89 (8.2) 310 (26.1)
 Paroxysmal AF 122 (11.2) 202 (17.0)
 Persistent AF 191 (17.6) 184 (15.5)
 Permanent AF 673 (61.9) 466 (39.3)
 Unclassified type of AF 12 (1.1) 25 (2.1)
Risk factors for embolism:
 Congestive heart failure 305 (28.1) 230 (19.4)
 Hypertension 812 (74.7) 720 (60.7)
 Diabetes mellitus 200 (18.4) 189 (15.9)
 Previous stroke or TIA or arterial embolism 301 (27.7) 204 (17.2)
 Vascular disease 238 (21.9) 240 (20.2)
 One or more risk factors for embolism 1063 (97.8) 1025 (86.4)
Risk factors for bleeding:
 Renal failure or liver failure 14 (1.3) 19 (1.6)
 Predisposition for bleedinga 216 (19.9) 389 (32.8)
 Inability to comply with INR monitoring 4 (0.4) 96 (8.1)
 Persistent uncontrolled hypertension 1 (0.1) 2 (0.2)
 Alcohol abuse 3 (0.3) 29 (2.4)
 No risk factors for bleeding 858 (78.9) 733 (61.8)
 Other indications for OAC treatmentb 126 (11.6) 25 (2.1)

Notes: OAC = oral anticoagulant. AF = atrial fibrillation. a = Previous intracranial haemorrhage, previous gastrointestinal bleeding, anaemia, thrombocytopenia, bleeding disorder, or other reasons for predisposition for bleeding (see Appendix). b = Chronic venous thromboembolism, mechanical or biological heart valve or planned cardioversion without other indications for OAC.